China (Mainland)
Premiumsupplier 
1032452-86-0 CAS NO.1032452-86-0
- Min.Order: 1 Metric Ton
- Payment Terms: T/T
- Product Details
Keywords
- 1032452-86-0
- 3-(2-chloropyriMidin-4-yl)-1-Methylindole
- Osimertinib
Quick Details
- ProName: 1032452-86-0
- CasNo: 1032452-86-0
- Molecular Formula: C13H10ClN3
- Appearance: detailed see specifications
- Application: Pharmaceutical intermediates
- DeliveryTime: enquiry
- PackAge: according to the clients requirement
- Port: chengdu
- ProductionCapacity: ton Metric Ton/Day
- Purity: 98%
- Storage: enquiry
- LimitNum: 1 Metric Ton
- Moisture Content: Less than 0.5%
- Impurity: enquiry
Superiority
Chengdu AstaTech Chemical Technology Co., Ltd. is a wholly-owned subsidiary of AstaTech (Chengdu) BioPharmaceutical Co., Ltd. It has overall accountability for AstaTech’s product list and sales and promotion of chemical reagents in China. The company has strong R&D ability and it has established APIs and APIs intermediate technology R&D system by hundreds of researchers including a dozen of domestic and foreign doctors and more than forty masters. At present, the company has obtained 13 science patents; developed more than thirty kinds of key intermediates for APIs have been listed and more than 8,000 kind of new-model intermediates for small-scale R&D of new drugs; has established production scale ranging from small experiment, to pilot and industrialization scale. At present, the company has more than ten series of products, 8,000 varieties of fine chemicals and more than 12,000 kinds of products in stock; meanwhile, the company also offer technical development and customized production services for pharmaceutical intermediates, electronic chemical intermediates and APIs to meet the needs of the market.
Details
Chengdu AstaTech Chemical Technology Co., Ltd. is a wholly-owned subsidiary of AstaTech (Chengdu) BioPharmaceutical Co., Ltd. It has overall accountability for AstaTech’s product list and sales and promotion of chemical reagents in China. The company has strong R&D ability and it has established APIs and APIs intermediate technology R&D system by hundreds of researchers including a dozen of domestic and foreign doctors and more than forty masters. At present, the company has obtained 13 science patents; developed more than thirty kinds of key intermediates for APIs have been listed and more than 8,000 kind of new-model intermediates for small-scale R&D of new drugs; has established production scale ranging from small experiment, to pilot and industrialization scale. At present, the company has more than ten series of products, 8,000 varieties of fine chemicals and more than 12,000 kinds of products in stock; meanwhile, the company also offer technical development and customized production services for pharmaceutical intermediates, electronic chemical intermediates and APIs to meet the needs of the market.
